Exiqon Announces Validation of a Biomarker Able to Distinguish Aggressive from Low-Risk Prostate Cancers

Exiqon Announces Validation of a Biomarker Able to Distinguish Aggressive from Low-Risk Prostate Cancers
Exiqon Life Sciences announced the publication of a study detailing the validation of its prognostic microRNA biomarker profile, an non-invasive way of distinguishing patients with aggressive prostate cancers from those with low-risk cancers. Researched and validated in a partnership with Aarhus University Hospital, the biomarker is intended to aid clinicians in determining the best treatment option

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *